SBFM vs. SCHG

Last updated Jun 23, 2026

SBFM (Sunshine Biopharma Inc) is a stock, while SCHG (Schwab U.S. Large-Cap Growth ETF) is Large Cap Growth Equities fund tracking the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. Over the past 10 years, SBFM returned -51.42%/yr vs 18.81%/yr for SCHG. At a 0.05 correlation, their price movements are largely independent.

Performance

SBFM vs. SCHG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sunshine Biopharma Inc (SBFM) and Schwab U.S. Large-Cap Growth ETF (SCHG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SBFM achieves a -83.33% return, which is significantly lower than SCHG's 2.76% return. Over the past 10 years, SBFM has underperformed SCHG with an annualized return of -51.42%, while SCHG has yielded a comparatively higher 18.81% annualized return.

SBFM

• 1D: -3.76%
• 1M: -57.41%
• YTD: -83.33%
• 6M: -85.14%
• 1Y: -85.76%
• 3Y*: -94.10%
• 5Y*: -77.19%
• 10Y*: -51.42%

SCHG

• 1D: -1.24%
• 1M: -2.59%
• YTD: 2.76%
• 6M: 2.11%
• 1Y: 20.89%
• 3Y*: 22.70%
• 5Y*: 13.68%
• 10Y*: 18.81%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SBFM vs. SCHG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SBFM Sunshine Biopharma Inc	-83.33%	-59.00%	-99.45%	-57.58%	994.95%	272.29%	3,388.89%	-97.19%	-93.28%	197.50%
SCHG Schwab U.S. Large-Cap Growth ETF	2.76%	17.50%	34.95%	50.10%	-31.80%	28.11%	39.14%	36.02%	-1.36%	28.05%

Correlation

The correlation between SBFM and SCHG is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.23
Correlation (3Y) Calculated over the trailing 3-year period	0.21
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (10Y) Calculated over the trailing 10-year period	0.10
Correlation (All Time) Calculated using the full available price history since Dec 11, 2009	0.05

The correlation between SBFM and SCHG shifts across timeframes, from 0.05 (all time) to 0.23 (1 year), reflecting how their relationship changes across market environments.

Return for Risk

SBFM vs. SCHG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBFM

SBFM Risk / Return Rank: 6
SBFM Sharpe Ratio Rank: 14
SBFM Sortino Ratio Rank: 7
SBFM Omega Ratio Rank: 5
SBFM Calmar Ratio Rank: 4
SBFM Martin Ratio Rank: 1

SCHG

SCHG Risk / Return Rank: 33
SCHG Sharpe Ratio Rank: 37
SCHG Sortino Ratio Rank: 35
SCHG Omega Ratio Rank: 35
SCHG Calmar Ratio Rank: 27
SCHG Martin Ratio Rank: 30

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBFM vs. SCHG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sunshine Biopharma Inc (SBFM) and Schwab U.S. Large-Cap Growth ETF (SCHG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SBFM	SCHG	Difference
Sharpe ratio: Return per unit of total volatility	-0.66	1.30	-1.96
Sortino ratio: Return per unit of downside risk	-1.41	1.79	-3.20
Omega ratio: Gain probability vs. loss probability	0.78	1.23	-0.45
Calmar ratio: Return relative to maximum drawdown	-0.95	1.28	-2.23
Martin ratio: Return relative to average drawdown	-1.98	4.19	-6.17

SBFM vs. SCHG - Sharpe Ratio Comparison

The current SBFM Sharpe Ratio is -0.66, which is lower than the SCHG Sharpe Ratio of 1.30. The chart below compares the historical Sharpe Ratios of SBFM and SCHG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SBFM vs. SCHG - Drawdown Comparison

The maximum SBFM drawdown since its inception was -100.00%, which is greater than SCHG's maximum drawdown of -34.59%. Use the drawdown chart below to compare losses from any high point for SBFM and SCHG.

Drawdown Indicators

	SBFM	SCHG	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	-34.59%	-65.41%
Max Drawdown (1Y) Largest decline over 1 year	-90.68%	-16.41%	-74.27%
Max Drawdown (3Y) Largest decline over 3 years	-99.98%	-23.39%	-76.59%
Max Drawdown (5Y) Largest decline over 5 years	-100.00%	-34.59%	-65.41%
Max Drawdown (10Y) Largest decline over 10 years	-100.00%	-34.59%	-65.41%
Current Drawdown Current decline from peak	-100.00%	-5.16%	-94.84%
Average Drawdown Average peak-to-trough decline	-88.84%	-5.20%	-83.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	43.21%	5.00%	+38.21%

Volatility

SBFM vs. SCHG - Volatility Comparison

Sunshine Biopharma Inc (SBFM) has a higher volatility of 56.48% compared to Schwab U.S. Large-Cap Growth ETF (SCHG) at 5.78%. This indicates that SBFM's price experiences larger fluctuations and is considered to be riskier than SCHG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBFM	SCHG	Difference
Volatility (1M) Calculated over the trailing 1-month period	56.48%	5.78%	+50.70%
Volatility (6M) Calculated over the trailing 6-month period	117.37%	12.50%	+104.87%
Volatility (1Y) Calculated over the trailing 1-year period	129.50%	16.21%	+113.29%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	6,611.20%	22.37%	+6,588.83%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	4,763.88%	21.61%	+4,742.27%

Dividends

SBFM vs. SCHG - Dividend Comparison

SBFM has not paid dividends to shareholders, while SCHG's dividend yield for the trailing twelve months is around 0.38%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SBFM Sunshine Biopharma Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SCHG Schwab U.S. Large-Cap Growth ETF	0.38%	0.36%	0.39%	0.46%	0.55%	0.42%	0.52%	0.82%	1.27%	1.01%	1.04%	1.22%

Frequently Asked Questions

Can I hold both SBFM and SCHG in my portfolio?

SBFM and SCHG have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SBFM or SCHG?

SBFM has higher volatility (56.48%) compared to SCHG (5.78%). In terms of maximum drawdown, SBFM dropped -100.00% vs SCHG's -34.59%.

Which has better risk-adjusted returns?

SCHG currently has the higher Sharpe Ratio (1.30 vs -0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.